TBX3 and breast carcinoma: Our data suggest that, in breast cancer cells, YAP1/β-catenin complex with TBX3, which phenocopies TBX5 at BCL2L1 and BIRC5 but additionally promotes cMYC expression, potentially by combining known TEAD- and TBX3-binding elements [28, 42].